These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 23788110)

  • 21. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
    Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
    Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
    Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
    Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
    Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
    Zheng L; Yang W; Zhang C; Ding WJ; Zhu H; Lin NM; Wu HH; He QJ; Yang B
    Cancer Lett; 2011 Oct; 309(1):27-36. PubMed ID: 21664043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.
    Meynet O; Bénéteau M; Jacquin MA; Pradelli LA; Cornille A; Carles M; Ricci JE
    Leukemia; 2012 May; 26(5):1145-7. PubMed ID: 22076465
    [No Abstract]   [Full Text] [Related]  

  • 27. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
    Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
    Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.
    Lickliter JD; Cox J; McCarron J; Martinez NR; Schmidt CW; Lin H; Nieda M; Nicol AJ
    Br J Cancer; 2007 Feb; 96(4):600-8. PubMed ID: 17311012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
    Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
    Kawashima-Goto S; Imamura T; Tomoyasu C; Yano M; Yoshida H; Fujiki A; Tamura S; Osone S; Ishida H; Morimoto A; Kuroda H; Hosoi H
    PLoS One; 2015; 10(7):e0132926. PubMed ID: 26172269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.
    Singh A; Jayanthan A; Farran A; Elwi AN; Kim SW; Farran P; Narendran A
    Leuk Res; 2011 Dec; 35(12):1649-57. PubMed ID: 21798596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
    Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.
    Lawlor KE; Smith SD; van Nieuwenhuijze A; Huang DC; Wicks IP
    J Leukoc Biol; 2011 Oct; 90(4):819-29. PubMed ID: 21719460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression.
    Lutz C; Mozaffari M; Tosevski V; Caj M; Cippà P; McRae BL; Graff CL; Rogler G; Fried M; Hausmann M
    Clin Exp Immunol; 2015 Aug; 181(2):343-56. PubMed ID: 25845418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
    Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
    J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
    Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
    J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BH3-mimetic ABT-737 inhibits allogeneic immune responses.
    Cippà PE; Kraus AK; Edenhofer I; Segerer S; Chen J; Hausmann M; Liu Y; Guimezanes A; Bardwell PD; Wüthrich RP; Fehr T
    Transpl Int; 2011 Jul; 24(7):722-32. PubMed ID: 21615547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
    Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM
    Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
    Al-Harbi S; Hill BT; Mazumder S; Singh K; Devecchio J; Choudhary G; Rybicki LA; Kalaycio M; Maciejewski JP; Houghton JA; Almasan A
    Blood; 2011 Sep; 118(13):3579-90. PubMed ID: 21772052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.